SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice

American Journal of Physiology - Renal Physiology

Volumn 290, Issue 4, 2006, Pages

  Sugaru, Eiji ^a   Nakagawa, Tsutomu ^a   Ono Kishino, Michiko ^a   Nagamine, Jun ^a   Tokunaga, Teruhisa ^a   Kitoh, Makoto ^a   Hume, W Ewan ^a   Nagata, Ryu ^a   Taiji, Mutsuo ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Antifibrotic agent; Diabetic nephropathy; Extracellular matrix; Transforming growth factor ; Urinary type IV collagen

Indexed keywords

5 CHLORO 2 [ 3 [2 (4 METHOXYBENZOYL) 4 METHYL 1H PYRROL 1 YL]PROP 1 EN 1 YL] N (METHYLSULFONYL) BENZAMIDE; ALBUMIN; ANTIFIBROTIC AGENT; COLLAGEN TYPE 4; DRUG VEHICLE; GLUCOSE; SMP 534; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; SMP-534;

ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; EXTRACELLULAR MATRIX; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; KIDNEY FAILURE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; URINALYSIS; URINE LEVEL; ALBUMINURIA; ANIMAL; ANIMAL FOOD; DISEASE MODEL; METABOLISM; MOUSE STRAIN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION;

ADMINISTRATION, ORAL; ALBUMINURIA; ANIMAL FEED; ANIMALS; BENZAMIDES; COLLAGEN TYPE IV; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; MICE; MICE, INBRED STRAINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33645735197     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00357.2005     Document Type: Article

References (48)

1. Adhikary L, Chow F, Nikolic-Paterson DJ, Stambe C, Dowling J, Atkins RC, and Tesch GH. Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 47: 1210-1222, 2004.
2. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 27: S79-S83, 2004.
3. Ayo SH, Radnik RA, Garoni JA, Glass 2nd WF, and Kreisberg JI. High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am J Pathol 136: 1339-1348, 1990.
4. Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med 116, Suppl 5A: 30S-38S, 2004.
5. Baricos WH, Cortez SL, Deboisblanc M, and Xin S. Transforming growth factor-β is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 10: 790-795, 1999.
6. Border WA, Okuda S, Languino LR, Sporn MB, and Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 346: 371-374, 1990.
7. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, and Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
8. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, and Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84: 491-495, 1996.
9. Chen L, Wang Y, Tay YC, and Harris DC. Proteinuria and tubulointerstitial injury. Kidney Int Suppl 61: S60-S62, 1997.
10. Chen S, Iglesias-de la Cruz MC, Jim B, Hong SW, Isono M, and Ziyadeh FN. Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice. Biochem Biophys Res Commun 300: 16-22, 2003.
11. Chiarelli F, Verrotti A, Mohn A, and Morgese G. The importance of microalbuminuria as an indicator of incipient diabetic nephropathy: therapeutic implications. Ann Med 29: 439-445, 1997.
12. Choi ME. Mechanism of transforming growth factor-β1 signaling. Kidney Int 77: S53-S58, 2000.
13. Cohen MP, Lautenslager GT, and Shearman CW. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic db/db mice. Metabolism 50: 1435-1440, 2001.
14. Cohen MP, Lautenslager GT, and Shearman CW. Increased collagen IV excretion in diabetes. A marker of compromised filtration function. Diabetes Care 24: 914-918, 2001.
15. Cohen MP, Sharma K, Jin Y, Hud E, Wu VY, Tomaszewski J, and Ziyadeh FN. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists: a novel treatment strategy. J Clin Invest 95: 2338-2345, 1995.
16. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, and Brenner BM. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65: 2309-2320, 2004.
17. Doggrell SA and Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 39: 89-105, 1998.
18. Falk RJ, Scheinman JI, Mauer SM, and Michael AF. Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. Diabetes 2: 34-39, 1983.
19. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, and Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51: 3090-3094, 2002.
20. Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG, Mogensen TH, Paludan SR, and Rasch R. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53: 166-172, 2004.
21. Gilbert RE, Cox A, Dziadek M, Cooper ME, and Jerums G. Extracellular matrix and its interactions in the diabetic kidney: a molecular biological approach. J Diabetes Complications 9: 252-254, 1995.
22. Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, and Ziyadeh FN. Increased glomerular and tubular expression of transforming growth factor-β1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 158: 1653-1663, 2001.
23. Ishimitsu T, Murayama N, Meguro T, Kageyama Y, Okada K, Okubo Y, Takeda S, Hasegawa K, Kikegawa Y, Ohwada T, Hosoya H, Minami J, Ono H, and Matsuoka H. Urinary excretions of albumin and type IV collagen in normotensive and hypertensive subjects. Hypertens Res 23: 459-466, 2000.
24. Iwano M, Kubo A, Nishino T, Sato H, Nishioka H, Akai Y, Kurioka H, Fujii Y, Kanauchi M, Shiiki H, and Dohi K. Quantification of glomerular TGF-β1 mRNA in patients with diabetes mellitus. Kidney Int 49: 1120-1126, 1996.
25. Kikkawa R, Togawa M, Isono M, Isshiki K, and Haneda M. Mechanism of the progression of diabetic nephropathy to renal failure. Kidney Int Suppl 62: S39-S40, 1997.
26. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, and Kikkawa R. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKCβ inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14: 439-447, 2000.
27. Laping NJ. ALK5 inhibition in renal disease. Curr Opin Pharmacol 3: 204-208, 2003.
28. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, and Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
29. Like AA, Lavine RL, Poffenbarger PL, and Chick WL. Studies in the diabetic mutant mouse. VI. Evolution of glomerular lesions and associated proteinuria. Am J Pathol 66: 193-224, 1972.
30. Lopez-Franco O, Suzuki Y, Sanjuan G, Blanco J, Hernandez-Vargas P, Yo Y, Kopp J, Egido J, and Gomez-Guerrero C. Nuclear factor-κB inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis. Am J Pathol 161: 1497-1505, 2002.
31. Miyazawa K, Shinozaki M, Hara T, Furuya T, and Miyazono K. Two major Smad pathways in TGF-β superfamily signalling. Genes Cells 7: 1191-1204, 2002.
32. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001.
33. Ravid M, Savin H, Jutrin I, Bental T, Katz B, and Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118: 577-581, 1993.
34. Reeves WB and Andreoli TE. Transforming growth factor β contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 97: 7667-7669, 2000.
35. Roberts AB, McCune BK, and Sporn MB. TGF-β: regulation of extracellular matrix. Kidney Int 41: 557-559, 1992.
36. Sharma K, McCue P, and Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 284: F1138-F1144, 2003.
37. Sugaru E, Sakai M, Horigome K, Tokunaga T, Kitoh M, Hume WE, Nagata R, Nakagawa T, and Taiji M. SMP-534 inhibits TGF-β-induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis. Am J Physiol Renal Physiol 289: F998-F1004, 2005.
38. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
39. Tsuruta Y, Morita H, Ito Y, Harada K, Matsumoto Y, Narita M, Komemushi S, Yamauchi S, Margolin SB, and Maeda K. Effect of pirfenidone on an acute phase of anti-Thy-1 nephritis. Clin Exp Nephrol 4: 306-312, 2000.
40. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998.
41. USRDS 1998 Annual Data Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH publication no. 98-3176).
42. Viberti G and Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106: 672-678, 2002.
43. Winer N and Sowers JR. Epidemiology of diabetes. J Clin Pharmacol 44: 397-405, 2004.
44. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, and Border WA. Expression of transforming growth factor-β isoforms in human glomerular disease. Kidney Int 49: 461-469, 1996.
45. Yu L, Noble NA, and Border WA. Therapeutic strategies to halt renal fibrosis. Curr Opin Pharmacol 2: 177-181, 2002.
46. Zhu D, Kim Y, Steffes MW, Groppoli TJ, Butkowski RJ, and Mauer SM. Glomerular distribution of type IV collagen in diabetes by high resolution quantitative immunochemistry. Kidney Int 45: 425-433, 1994.
47. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, and Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression and glomerular mesangial matrix expression by treatment with monoclonal anti-TGF-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020, 2000.
48. Ziyadeh FN, Sharma K, Ericksen M, and Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest 93: 536-542, 1994.